Favezelimab - Merck Sharp & Dohme
Alternative Names: Mavezelimab - Merck Sharp & Dohme; MK-4280Latest Information Update: 22 Jan 2024
At a glance
- Originator Merck Sharp & Dohme
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Haematological malignancies; Non-small cell lung cancer
- No development reported Solid tumours
Most Recent Events
- 09 Dec 2023 Efficacy and adverse events data from a phase I/II trial in Haematological malignancies presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 09 Dec 2023 Efficacy and adverse events data from a phase I/II trial in Haematological malignancies presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Canada (IV, Infusion)